Etzer Darout
Stock Analyst at BMO Capital
(3.87)
# 614
Out of 4,670 analysts
93
Total ratings
47.14%
Success rate
11.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Etzer Darout
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Maintains: Outperform | $90 → $88 | $25.86 | +240.29% | 2 | Nov 20, 2024 | |
| ACRV Acrivon Therapeutics | Maintains: Outperform | $28 → $27 | $6.55 | +312.21% | 7 | Nov 14, 2024 | |
| NUVL Nuvalent | Maintains: Outperform | $132 → $134 | $94.93 | +41.16% | 6 | Nov 13, 2024 | |
| XNCR Xencor | Reiterates: Outperform | $32 → $34 | $25.01 | +35.95% | 5 | Nov 8, 2024 | |
| GMAB Genmab | Reiterates: Outperform | $46 → $48 | $20.65 | +132.45% | 3 | Nov 8, 2024 | |
| NVS Novartis AG | Maintains: Market Perform | $118 → $120 | $104.28 | +15.07% | 3 | Oct 30, 2024 | |
| EXEL Exelixis | Maintains: Outperform | $29 → $36 | $35.61 | +1.10% | 2 | Oct 30, 2024 | |
| SRRK Scholar Rock Holding | Maintains: Outperform | $34 → $38 | $29.92 | +27.01% | 3 | Oct 11, 2024 | |
| TERN Terns Pharmaceuticals | Reiterates: Outperform | $19 → $26 | $5.79 | +349.05% | 4 | Sep 16, 2024 | |
| YMAB Y-mAbs Therapeutics | Maintains: Outperform | $26 → $25 | $10.41 | +140.15% | 6 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $8 → $5 | $3.24 | +54.32% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $4.25 | +370.59% | 3 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $84 → $91 | $45.49 | +100.04% | 5 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $7 → $6 | $2.29 | +162.01% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3.25 → $3.59 | $0.89 | +303.37% | 10 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $123 → $122 | $113.13 | +7.84% | 3 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $80 → $82 | $65.63 | +24.94% | 4 | Apr 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.62 | +358.89% | 2 | Sep 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $19 | $7.84 | +142.35% | 2 | Apr 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $170 | $244.89 | -30.58% | 2 | Feb 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $84 | $4.85 | +1,631.96% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $54 | $32.73 | +64.99% | 1 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $27 → $38 | $44.73 | -15.05% | 2 | Sep 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $54 → $52 | $3.80 | +1,268.42% | 1 | Mar 28, 2018 |
Arvinas
Nov 20, 2024
Maintains: Outperform
Price Target: $90 → $88
Current: $25.86
Upside: +240.29%
Acrivon Therapeutics
Nov 14, 2024
Maintains: Outperform
Price Target: $28 → $27
Current: $6.55
Upside: +312.21%
Nuvalent
Nov 13, 2024
Maintains: Outperform
Price Target: $132 → $134
Current: $94.93
Upside: +41.16%
Xencor
Nov 8, 2024
Reiterates: Outperform
Price Target: $32 → $34
Current: $25.01
Upside: +35.95%
Genmab
Nov 8, 2024
Reiterates: Outperform
Price Target: $46 → $48
Current: $20.65
Upside: +132.45%
Novartis AG
Oct 30, 2024
Maintains: Market Perform
Price Target: $118 → $120
Current: $104.28
Upside: +15.07%
Exelixis
Oct 30, 2024
Maintains: Outperform
Price Target: $29 → $36
Current: $35.61
Upside: +1.10%
Scholar Rock Holding
Oct 11, 2024
Maintains: Outperform
Price Target: $34 → $38
Current: $29.92
Upside: +27.01%
Terns Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $19 → $26
Current: $5.79
Upside: +349.05%
Y-mAbs Therapeutics
Aug 13, 2024
Maintains: Outperform
Price Target: $26 → $25
Current: $10.41
Upside: +140.15%
Aug 7, 2024
Maintains: Market Perform
Price Target: $8 → $5
Current: $3.24
Upside: +54.32%
Aug 6, 2024
Reiterates: Outperform
Price Target: $20
Current: $4.25
Upside: +370.59%
Jun 4, 2024
Maintains: Outperform
Price Target: $84 → $91
Current: $45.49
Upside: +100.04%
May 10, 2024
Maintains: Market Perform
Price Target: $7 → $6
Current: $2.29
Upside: +162.01%
May 9, 2024
Maintains: Market Perform
Price Target: $3.25 → $3.59
Current: $0.89
Upside: +303.37%
May 7, 2024
Maintains: Outperform
Price Target: $123 → $122
Current: $113.13
Upside: +7.84%
Apr 26, 2024
Maintains: Outperform
Price Target: $80 → $82
Current: $65.63
Upside: +24.94%
Sep 1, 2023
Reiterates: Buy
Price Target: $12
Current: $2.62
Upside: +358.89%
Apr 25, 2023
Maintains: Outperform
Price Target: $20 → $19
Current: $7.84
Upside: +142.35%
Feb 3, 2022
Upgrades: Buy
Price Target: $170
Current: $244.89
Upside: -30.58%
Jul 12, 2021
Initiates: Buy
Price Target: $84
Current: $4.85
Upside: +1,631.96%
Feb 26, 2021
Initiates: Buy
Price Target: $54
Current: $32.73
Upside: +64.99%
Sep 9, 2020
Maintains: Buy
Price Target: $27 → $38
Current: $44.73
Upside: -15.05%
Mar 28, 2018
Maintains: Outperform
Price Target: $54 → $52
Current: $3.80
Upside: +1,268.42%